Developments in virus-like particle-based vaccines for infectious diseases and cancer

@article{Buonaguro2011DevelopmentsIV,
  title={Developments in virus-like particle-based vaccines for infectious diseases and cancer},
  author={Luigi Buonaguro and Maria Tagliamonte and Maria Lina Tornesello and Franco Maria Buonaguro},
  journal={Expert Review of Vaccines},
  year={2011},
  volume={10},
  pages={1569 - 1583}
}
Virus-like particles hold great promise for the development of effective and affordable vaccines. Indeed, virus-like particles are suitable for presentation and efficient delivery of linear as well as conformational antigens to antigen-presenting cells. This will ultimately result in optimal B-cell activation and cross-presentation with both MHC class I and II molecules to prime CD4+ T-helper as well as CD8+ cytotoxic T cells. This article provides an update on the development and use of virus… 
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection
HIV-1 virus-like particles (VLPs) are promising vaccine candidates against HIV-1 infection. They are capable of preserving the native conformation of HIV-1 antigens and priming CD4+ and CD8+ T cell
Design of novel vaccines based on virus-like particles or chimeric virions.
TLDR
This chapter provides an overview on the design and use of VLPs for the development of new generation vaccines.
Development of HPV next-generation virus-like particle vaccines that are cross-protective
Virus-like particles (VLPs) comprised of viral structural proteins that selfassemble into particles resembling the native virion represent a relatively novel vaccine development strategy. Both safe
Influenza virosomes as vaccine adjuvant and carrier system
TLDR
A second generation of influenza virosomes has evolved as a carrier and adjuvant system, which is currently applied in preclinical and clinical stage vaccine candidates targeting various prophylactic and therapeutic indications.
Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines
TLDR
The present review summarizes the categories of nanoparticles and peptide cancer vaccines which are currently under pre-clinical evaluation and shows that the immunogenicity of peptide-based cancer vaccines can be significantly potentiated by nanoparticles.
Virus like particle-based vaccines against emerging infectious disease viruses
TLDR
Recent developments with VLP-based vaccines for several highly virulent emerging or re-emerging infectious diseases are reviewed.
Virus Like Particles as Immunogens and Universal Nanocarriers.
TLDR
Different approaches for of virus-like particle synthesis and manipulation, as well as their potential applications, will be discussed.
Plant-derived virus-like particles as vaccines
TLDR
The essential role of plants as a novel, speedy and economical production platform for VLP-based vaccines and the promising implications of the recent creation of “humanized” glycosylation plant lines are discussed.
Virus-like particles produced in plants as potential vaccines
TLDR
The history of VLP production in plants is covered, and a few examples in detail are explored to illustrate the potential of such a mode of production for human and animal medicine.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 257 REFERENCES
Virus-like particles as particulate vaccines.
TLDR
The present review will address the biological and immunological properties of particulate structures, in particular VLPs, as platform for vaccine development.
Vaccines that facilitate antigen entry into dendritic cells
TLDR
Combined vaccines of the future could use adjuvants such as virus‐like particles and particles targeted towards a predominant cellular type or immune response, with target cell activation enhanced by growth factors or maturation signals prior to, or during immunization.
Virus-like particle vaccines and adjuvants: the HPV paradigm
TLDR
The immunological results obtained with the inclusion of monophosphoryl lipid A adjuvant in the formulation of L1-based human papillomavirus-naked virus-like particles to reduce a Th1 cellular immunity impairment are peculiar for alum-derived adjuvants, along with the induction of highly enhanced humoral and memory B-cellular immunity.
Virus-Like Particles as Carriers for T-Cell Epitopes: Limited Inhibition of T-Cell Priming by Carrier-Specific Antibodies
TLDR
The data show that VLP-specific antibodies did not measurably reduce antigen presentation in vitro or in vivo, and T-cell priming was slightly reduced by antigen- specific antibodies; however, the overall reduction was limited and vaccination with VLPs in the presence of VLP -specific antibodies still resulted in protective T- cell responses.
In vitro gene transfer using human papillomavirus-like particles.
TLDR
It is reported here that human papillomavirus-like particles composed of the major capsid protein (L1) of HPV-16 are able to package unrelated plasmid DNA in vitro and then to deliver this foreign DNA to eukaryotic cells with the subsequent expression of the encoded gene.
Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion
TLDR
Data show that retroviral Gag particles can be used as antigen presentation vehicles and elicited a strong anti-Gag antibody response and a weak antibody response to the V3 region.
Recent advances in cancer vaccines: an overview.
TLDR
A personalized approach to boost immune responses, addition of chemotherapy to overcome robust cancers and changing of endpoints from tumor reduction to overall survival seem to be the three key elements for the development of therapeutic cancer vaccines.
...
1
2
3
4
5
...